Skip to main content
Clinical Trials/CTRI/2020/01/022798
CTRI/2020/01/022798
Recruiting
Phase 3

A prospective, randomized, double-blind, twoarm,active-controlled, parallel, multicentre,non-inferiority phase III clinical trial to assessthe efficacy and safety of Avanafil ascompared to Sildenafil in patients with ErectileDysfunction

Zydus Healthcare Ltd0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: N529- Male erectile dysfunction, unspecified
Sponsor
Zydus Healthcare Ltd
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients 21 years of age and above
  • 2\. Patients with history of erectile dysfunction (defined as inability to attain
  • and/or maintain penile erection sufficient for satisfactory sexual performance)
  • for at least 3 months
  • 3\. Patients meeting the diagnostic criteria for erectile dysfunction as per the
  • international index of erectile function\-Erectile Function Domain (IIEF\-EF)
  • score lesser than 26
  • 4\. Patients in heterosexual, monogamous steady relationship since last 6
  • 5\. Patients willing to provide written informed consent and comply with the
  • protocol requirements

Exclusion Criteria

  • 1\. Patients engaged in polygamy and homosexual relationships
  • 2\. Patients who have used PDE5 inhibitors or any other drug for erectile
  • dysfunction in last 4 weeks
  • 3\. Patients who have tried PDE5 inhibitors in past and have discontinued either
  • due to lack of efficacy or significant side effects
  • 4\. Patients with known hypersensitivity to sildenafil, avanafil or other PDE5
  • 5\. Patients with cardiovascular disorder like unstable angina, angina, resting or
  • postural hypotension ( \< 90/50 mmHg), uncontrolled hypertension ( \> 170/100
  • mmHg) and with a history of myocardial infarction, arrhythmia, coronary
  • revascularization in last 6 months

Outcomes

Primary Outcomes

Not specified

Similar Trials